feed,title,long_url,short_url
Investors,Apogee Reverses Lower Despite Promise For Twice-Yearly Eczema Shot,https://www.investors.com/news/technology/apogee-therapeutics-eczema-shot/,
Investors,KalVista Ends Its Unexpectedly Messy Path To Approval In HAE Treatment,https://www.investors.com/news/technology/kalvista-pharmaceuticals-fda-approval-ekterly/,
Investors,Amazon Prime Day Kicks Off Tomorrow. Here's How Much Shoppers Are Expected To Spend.,https://www.investors.com/news/technology/amazon-stock-amazon-prime-day-projections/,
